Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma

Jean Pierre Delord*, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Kudchakar, Amit Mahipal, Yasuhide Yamada, Ryan Sullivan, Ana Arance, Richard F. Kefford, Matteo S. Carlino, Manuel Hidalgo, Carlos Gomez-Roca, Daniela Michel, Abdelkader Seroutou, Vassilios Aslanis, Giordano Caponigro, Darrin D. Stuart, Laure Moutouh-De Parseval, Tim DemuthReinhard Dummer

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    141 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma'. Together they form a unique fingerprint.

    Medicine & Life Sciences